Lauren V. Wood

University of Alabama at Birmingham — United States

Immunology and Microbiology · Life Sciences

31h-index2.6kcitations119works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(39), Cancer Immunotherapy and Biomarkers(21), Prostate Cancer Treatment and Research(20), HIV/AIDS Research and Interventions(17), HIV/AIDS drug development and treatment(15)

Publications119 total

Enhanced Recovery Program Adherence: Which Components are Associated with Cost Saving?
Journal of the American College of Surgeons·2026
48Immunotherapy response correlates in metastatic clear cell renal cell carcinoma from circulating cell-free epigenomes
The Oncologist·2025Open Access
27 | MOSUNETUZUMAB (MOSUN) PRODUCES DURABLE BENEFIT IN PATIENTS (PTS) WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA (FL): EXTENDED FOLLOW UP OF THE MITHIC‐FL1 TRIAL
Hematological Oncology·2025Open Access
Mo2093: ASSESSING THE QUALITY OF YOUTUBE VIDEOS ON CELIAC DISEASE DELIVERED BY EXPERTS VS. NON-EXPERTS
Gastroenterology·2025· 1 cited
597 Vaccine antigen-specific T cell responses persisted several years after initial vaccination in patients with prostate cancer who re-enrolled to a subsequent study involving multiepitope vaccination
Regular and Young Investigator Award Abstracts·2024Open Access
A Vaccine (PDS0101) Alone or in Combination with Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
International Journal of Radiation Oncology*Biology*Physics·2024· 1 cited
Potent CD8+ T-Cell Proliferation and Effector Differentiation Following Subcutaneous (SC) Mosunetuzumab Administration in Patients with Untreated, High Tumor-Burden Follicular Lymphoma (FL)
Blood·2023
Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC).
Journal of Clinical Oncology·2023· 8 cited
Supplemental file 1 from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
2023Open Access
Supplemental Figure 3 from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
2023Open Access
Supplemental Figure 3 from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
2023Open Access
Supplemental Figure legends from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
2023Open Access
Supplemental Figure 2 from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
2023Open Access
Data from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
2023Open Access
Supplemental file 1 from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
2023Open Access
Supplementary results from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
2023Open Access
Supplemental Figure 2 from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
2023Open Access
Supplemental Figure 1 from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
2023Open Access
Supplemental Figure legends from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
2023Open Access
Data from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Seth M. Steinberg(7), Thomas J. Walsh(6), Brigitta U. Mueller(6), Jay A. Berzofsky(6), David F. Stroncek(6), Andreas H. Groll(5), David Venzon(5), Pim Brouwers(5), Staci Martin(5), Pamela L. Wolters(5), Shizuko Sei(5), Paul Jarosinski(5), Corina Gonzalez(5), Masaki Terabe(5), Gregg Roby(4), Philip A. Pizzo(4), Sheryl Zwerski(4), James L. Gulley(4), Marianna Sabatino(4), Christine C. Chiou(3)